CNS vs XENE: Which Is the Better Buy in 2026?
Last updated August 2026
Short answer
CNS (Cohen & Steers) and XENE (Xenon Pharmaceuticals) share investment themes but are different businesses. The right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme.
CNS vs XENE: the tie-breaker metrics
Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | CNS | XENE | What it tells you |
|---|---|---|---|
| Forward P/E | 21.15 | -12.46 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 1.22 | 0.61 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 90% of range | 76% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 7.51 | 8.62 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how CNS and XENE affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CNS and XENE share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CNS and XENE exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Cohen & Steers (CNS) do?
Cohen & Steers is a global investment manager founded in 1986 that specializes in real assets and alternative income, including listed real estate (REITs), infrastructure, preferred securities, and multi-strategy real assets. It organized the first US real estate securities mutual fund and remains one of the largest managers of REIT securities in the world, with roughly two-thirds of assets in listed real estate. The firm earns management fees on the assets it runs across open-end funds, closed-end funds, institutional accounts, and newer vehicles like its non-traded REIT (CNSREIT).
What does Xenon Pharmaceuticals (XENE) do?
Xenon Pharmaceuticals is a Burnaby, Canada based, US-listed neuroscience biotech developing treatments for epilepsy and neuropsychiatric conditions. Its lead asset is azetukalner (formerly XEN1101), a potent KV7 potassium channel opener that, if approved, would be the only channel opener of its kind among antiseizure medications. The company is running a broad Phase 3 program spanning focal onset seizures, primary generalized tonic-clonic seizures, and neuropsychiatric indications including major depressive disorder and bipolar depression.
CNS vs XENE: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- CNS drivers: Rate-cut tailwind for real assets; Return to organic growth.
- XENE drivers: Azetukalner FDA filing and launch; Pipeline breadth beyond focal epilepsy.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: CNS revenue is almost entirely tied to AUM, so equity or bond market drawdowns directly cut fees and earnings. For XENE, xenon has no approved product and no meaningful revenue, so the entire valuation rests on azetukalner clearing regulatory review and selling once launched.
CNS or XENE: which should you pick?
CNS vs XENE: the full fundamentals
CNS. As of April 2026, CNS traded around a mid-20s price-to-earnings multiple with a dividend yield near 3.7%, reflecting its status as a profitable, dividend-paying specialty manager. Q1 2026 revenue of about $145.6 million grew roughly 8% year over year, and operating margin improved to about 34%. Because fees scale with AUM, valuation and earnings hinge on the direction of markets and flows into real-asset strategies.
XENE. Xenon trades as a pre-revenue biotech, so traditional multiples like price-to-earnings do not apply and the roughly $5 billion market cap reflects expectations for azetukalner rather than current financials. The company burns cash by design to fund Phase 3 trials and a commercial build, offset by a roughly $1.34 billion cash position that funds operations into 2029. Valuation moves with clinical and regulatory milestones far more than with quarterly results.
Headline figures (approximate, APRIL 2026): CNS shows assets under management ~$93.1B, revenue (q1 2026) ~$145.6M, q1 2026 net inflows ~$497M, diluted eps (q1 2026) ~$0.82; XENE shows market cap ~$5.0B, product revenue ~$0 (pre-commercial), net loss (q1 2026) ~$102M, net loss (fy 2025) ~$346M.
The bottom line: CNS vs XENE
CNS and XENE are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CNS and XENE exposure against your real portfolio. It is not an investment adviser.
Wondering how CNS or XENE fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in Cohen & Steers with AI
Connect the broker you already use and ask Walnut's AI how CNS fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between CNS and XENE?
+
Cohen & Steers is a global investment manager founded in 1986 that specializes in real assets and alternative income, including listed real estate (REITs), infrastructure, preferred securities, and multi-strategy real assets. Xenon Pharmaceuticals is a Burnaby, Canada based, US-listed neuroscience biotech developing treatments for epilepsy and neuropsychiatric conditions. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is CNS or XENE the better stock?
+
Neither is universally better; they suit different views and risk levels. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, CNS or XENE?
+
On forward P/E (as of August 2026), CNS trades at 21.15x and XENE at -12.46x, so XENE is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both CNS and XENE?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of CNS vs XENE?
+
CNS: CNS revenue is almost entirely tied to AUM, so equity or bond market drawdowns directly cut fees and earnings. Its concentration in real estate and rate-sensitive income means a reversal to higher-for-longer rates, or a rotation away from REITs and preferreds, could trigger outflows and market depreciation at the same time. The active-management fee model faces secular pressure from low-cost passive and index products, and net flows can turn negative in stressed markets. Newer private and non-traded initiatives add execution and liquidity risk, and results can be lumpy quarter to quarter. XENE: Xenon has no approved product and no meaningful revenue, so the entire valuation rests on azetukalner clearing regulatory review and selling once launched. Clinical-stage biotech carries binary risk: a filing delay, an FDA setback, or disappointing data in the generalized seizure or neuropsychiatric programs could sharply reset the stock. Even with approval, azetukalner would enter a crowded antiseizure market with established generics and branded competitors, so commercial uptake is uncertain. The company continues to post large net losses (about $102 million in Q1 2026), and while the cash runway extends into 2029, further dilution is possible if programs expand or slip. The shares are volatile and sensitive to single data points.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell CNS or XENE; figures are approximate and dated (as of August 2026). Verify current data before investing.